AML
Clinical trials for AML explained in plain language.
Never miss a new study
Get alerted when new AML trials appear
Sign up with your email to follow new studies for AML, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New Three-Drug cocktail aims to boost remission in leukemia patients
Disease control Not yet recruitingThis early-phase trial tests a combination of three drugs (venetoclax, azacitidine, and liposomal mitoxantrone) as a first treatment for adults with newly diagnosed acute myeloid leukemia (AML). The goal is to see if this mix is safe and improves remission rates. About 30 partici…
Matched conditions: AML
Phase: NA • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated May 26, 2026 10:33 UTC
-
New hope for tough leukemia: drug combo trial opens
Disease control Not yet recruitingThis study tests a combination of two drugs (AZA and APG1252) in 52 adults with high-risk acute myeloid leukemia (AML). The goal is to see if the combo is safe and can help control the disease. Participants include those whose cancer returned or didn't respond to prior treatment,…
Matched conditions: AML
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 26, 2026 10:29 UTC
-
New combo therapy aims to keep AML in remission longer
Disease control Not yet recruitingThis study tests whether adding venetoclax to azacitidine as maintenance therapy helps prevent relapse in people with acute myeloid leukemia (AML) who are already in remission after initial treatment. About 788 participants aged 14 to 74 will be randomly assigned to receive eithe…
Matched conditions: AML
Phase: PHASE3 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated May 26, 2026 10:25 UTC
-
Two-Punch therapy takes on tough leukemia
Disease control Not yet recruitingThis study tests a two-step treatment for people with a tough type of leukemia (AML) that has come back or not responded to standard chemo. First, patients receive a special immune cell therapy (CLL1 CAR-T) to target cancer cells, followed by a stem cell transplant to rebuild a h…
Matched conditions: AML
Phase: NA • Sponsor: Donghua Zhang • Aim: Disease control
Last updated May 20, 2026 12:08 UTC
-
New app aims to guide young cancer survivors through After-Treatment challenges
Knowledge-focused Not yet recruitingThis study is testing a mobile app called my.naviGATE for teens and young adults (ages 15-24) who have finished cancer treatment. The app provides personalized education, peer support, and tracks how patients are doing. Researchers want to see if using the app helps patients feel…
Matched conditions: AML
Phase: NA • Sponsor: Dana-Farber Cancer Institute • Aim: Knowledge-focused
Last updated May 15, 2026 11:54 UTC